Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 6.96
-3.2 %
$ 161 M
Market Cap
-9.67
P/E
1. INTRINSIC VALUE
Balance Sheet
Journey Medical Corporation
| Current Assets | 48.2 M |
| Cash & Short-Term Investments | 20.3 M |
| Receivables | 10.2 M |
| Other Current Assets | 17.6 M |
| Non-Current Assets | 32.1 M |
| Long-Term Investments | 0 |
| PP&E | 199 K |
| Other Non-Current Assets | 31.9 M |
| Current Liabilities | 35.2 M |
| Accounts Payable | 16 M |
| Short-Term Debt | 166 K |
| Other Current Liabilities | 19 M |
| Non-Current Liabilities | 25 M |
| Long-Term Debt | 236 K |
| Other Non-Current Liabilities | 24.8 M |
EFFICIENCY
Earnings Waterfall
Journey Medical Corporation
| Revenue | 56.1 M |
| Cost Of Revenue | 0 |
| Gross Profit | 56.1 M |
| Operating Expenses | 69.8 M |
| Operating Income | -13.7 M |
| Other Expenses | 995 K |
| Net Income | -14.7 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Journey Medical Corporation
| Net Income | -14.7 M |
| Depreciation & Amortization | 3.73 M |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.1 M |
| Change in Working Capital | 0 |
| Others | -4.28 M |
| Free Cash Flow | -9.13 M |
Wall Street Analysts Price Targets
Journey Medical Corporation
Wall Street analysts predict an average 1-year price target for DERM of $10.5 , with forecasts ranging from
a
low of
$10.5 to a high of $10.5 .
DERM Lowest Price Target
Wall Street Target
10.5 USD
50.86%
DERM Average Price Target
Wall Street Target
10.5 USD
50.86%
DERM Highest Price Target
Wall Street Target
10.5 USD
50.86%
4. DIVIDEND
ANALYSIS
DERM does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Journey Medical Corporation
Sold
0-3 MONTHS
818 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
72.9 K USD 1
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer
SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer (“COO”). Mr. Alloush will continue to also serve as the Company's General Counsel.
globenewswire.com
- 2 weeks ago
Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - Roth Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
seekingalpha.com
- 3 weeks ago
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates
Journey Medical Corporation (DERM) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.12 per share a year ago.
zacks.com
- 3 weeks ago
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz.
globenewswire.com
- 3 weeks ago
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults.
globenewswire.com
- 4 weeks ago
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 26, 2025 at 4:30 p.m. ET
globenewswire.com
- 1 month ago
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California.
globenewswire.com
- 1 month ago
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks
globenewswire.com
- 1 month ago
Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida
U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024 U.S. FDA approved Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults in November 2024
globenewswire.com
- 1 month ago
Stock Picks From Seeking Alpha's January 2025 New Analysts
In January, Seeking Alpha welcomed 29 new analysts. This article introduces them and showcases some of their top picks. Analysts highlighted include The Conservative Investor recommending Dassault Aviation, Christopher Gray on ASML Holding, and Inflexio Research on Bragg Gaming Group, all rated as Buys. Analysts' diverse backgrounds span sectors like technology, finance, and consumer staples, with investment strategies focusing on value, growth, and special situations.
seekingalpha.com
- 2 months ago
Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point
Journey Medical's future hinges on Emrosi™, a new formulation of minocycline for rosacea, showing superior efficacy over Oracea® in Phase III trials. Despite current financial challenges and a need for additional funding, Emrosi's market exclusivity until 2039 and strong trial results offer significant potential. Dermatologists' acceptance and PBM positioning are crucial for Emrosi's success, given its proven efficacy and potential to replace Oracea.
seekingalpha.com
- 2 months ago
Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea
Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T. Conference call and webcast scheduled to take place on Wednesday, February 5, 2025, at 4:30 p.m. E.T.
globenewswire.com
- 2 months ago
8. Profile
Summary
Journey Medical Corporation DERM
COUNTRY
US
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 161 M
Dividend Yield
0.00%
Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Contact
9237 East Via de Ventura Boulevard, Scottsdale, AZ, 85258
https://journeymedicalcorp.com
IPO
Date
Nov. 12, 2021
Employees
41
Officers
Mr. Claude Maraoui
Founder, President, Chief Executive Officer & Director
Mr. Joseph M. Benesch
Chief Financial Officer & Corporate Controller
Dr. Lindsay Allan Rosenwald
Executive Chairman